[1] 骆抗先. 乙型肝炎基础和临床[M]. 北京:人民卫生出版社,2006:233.
[2] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022 年版)[J].中华肝脏病杂志, 2022, 30(12): 1309-1331.
[3] McMahon B J, Nolen L D, Snowball M, et al. HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: the hepatitis B Alaska study[J]. Hepatology, 2021,74(6):2965-2973.
[4] Campbell C, Wang T, McNaughton A L, et al. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis[J]. J Viral Hepat, 2021, 28(3): 493-507.
[5] 鲁凤民, 封波, 郑素军, 等. 核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究现状[J]. 临床肝胆病杂志, 2021, 37(6): 1268-1274.
[6] Sun Y, Wu X, Zhou J, et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy[J]. Clin Gastroenterol Hepatol, 2020, 18(11): 2582-2591.
[7] Zhang Q, Peng H, Liu X, et al. Chronic hepatitis B infection with low level viremia correlates with the progression of the liver disease[J]. J Clin Transl Hepatol, 2021, 9(6): 850-859.
[8] Jang J W, Choi J Y, Kim Y S, et al. Effects of virologic response to treatment on short and long-term outcomes of patients with chronic hepatitis B virus infection and decompensated cirrhosis[J]. Clin Gastroenterol Hepatol, 2018, 16(12):1954-1963.
[9] Kim J H, Sinn D H, Kang W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology, 2017, 66(2):335-343.
[10] Zhang Q, Peng H, Liu X, et al. Chronic hepatitis B infection with low level viremia correlates with the progression of the liver disease[J]. J Clin Transl Hepatol, 2021, 9(6):850-859.
[11] Kim J H, Sinn D H, Kang W,et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology, 2017, 66(2):335-343.
[12] 陈姝延, 孙亚朦, 周家玲, 等. 长期抗病毒治疗乙型肝炎肝硬化患者的组织学逆转率和临床改善情况[J]. 中华肝脏病杂志, 2022, 30(6): 583-590.
[13] Gui H L, Zhao C Q, Wang Y, et al. Histological outcome of fuzheng huayu plus entecavir combination therapy in chronic hepatitis B patients with significant liver fibrosis[J]. J Clin Transl Hepatol, 2020, 8 (3): 277-284.
[14] Papatheodoridis G V, Petraki K, Cholongitas E, et al. Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B[J]. J Viral Hepat, 2005,12 (2): 199-206.
[15] 程能能. 我国首个原研口服抗HBV药物TMF结构优势解读——神奇的甲基化[J]. 肝脏, 2021, 26(12): 1303-1305.
[16] Liu Z, Jin Q, Zhang Y, et al. 96-Week treatment of tenofovir amibufenamide and tenofovir disoproxil fumarate in chronic hepatitis B patients[J]. J Clin Transl Hepatol, 2022, 11(3):649-660.
[17] Li L, Zhou J, Li Y, et al. Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a etrospective real-world study[J]. Front Pharmacol, 2023, 14:1165990.
[18] Peng W T, Jiang C, Yang F L, et al. Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: a real-world study[J]. World J Gastroenterol, 2023, 29(44): 5907-5918.
[19] Chen E Q, Li L Q, Zhou J, et al. Switching to TMF is effective for ETV or TAF monotherapy in patients with hypoviremia[J]. APASL, 2024, 32(S1):14-18.
[20] 吕雪艳,陈如悦,潘亚杰,等.艾米替诺福韦治疗乙型肝炎病毒相关肝硬化患者的早期疗效及安全性研究[J].延安大学学报:医学科学版, 2023, 21(3):74-82.
[21] Rong X, Yang G, Xu Y, et al. Efficacy and safety of tenofovir amibufenamide and tenofovir alafenamide for first-time HBV-related decompensated cirrhosis[J]. J Viral Hepat, 2025, 32(4):e14029. |
